Trial Profile
Compassionate-use programme/early access programme for cabazitaxel + prednisone in men with metastatic castration-resistant prostate cancer who had progressed on docetaxel
Status:
Active, no longer recruiting
Phase of Trial:
Clinical Phase Unknown
Latest Information Update: 20 May 2014
Price :
$35
*
At a glance
- Drugs Cabazitaxel (Primary) ; Prednisone (Primary)
- Indications Prostate cancer
- Focus Adverse reactions
- Sponsors Sanofi
- 20 May 2014 New trial record
- 31 Jan 2014 Results (n=746 as of 31 August 2011) published in the European Journal of Cancer
- 01 Oct 2013 Results for 1301 patients presented at the 2013 European Cancer Congress.